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CYP3A4 is the most important drug metabolizing enzyme in adult humans because of
its prominent expression in liver and gut and because of its broad substrate specificity,
which includes drugs from most therapeutic categories and many endogenous substances.
Expression and function of CYP3A4 vary extensively both intra- and interindividually thus
contributing to unpredictable drug response and toxicity. A multitude of environmental,
genetic, and physiological factors are known to influence CYP3A4 expression and activ-
ity. Among the best predictable sources of variation are drug–drug interactions, which are
either caused by pregnane X-receptor (PXR), constitutive androstane receptor (CAR) medi-
ated gene induction, or by inhibition through coadministered drugs or other chemicals,
including also plant and food ingredients. Among physiological and pathophysiological fac-
tors are hormonal status, age, and gender, the latter of which was shown to result in higher
levels in females compared to males, as well as inflammatory processes that downregu-
late CYP3A4 transcription. Despite the influence of these non-genetic factors, the genetic
influence on CYP3A4 activity was estimated in previous twin studies and using information
on repeated drug administration to account for 66% up to 88% of the interindividual varia-
tion. Although many single nucleotide polymorphisms (SNPs) within the CYP3A locus have
been identified, genetic association studies have so far failed to explain a major part of the
phenotypic variability.The term “missing heritability” has been used to denominate the gap
between expected and known genetic contribution, e.g., for complex diseases, and is also
used here in analogy. In this review we summarize CYP3A4 pharmacogenetics/genomics
from the early inheritance estimations up to the most recent genetic and clinical studies,
including new findings about SNPs in CYP3A4 (∗22) and other genes (P450 oxidoreductase
(POR), peroxisome proliferator-activated receptor alpha (PPARA)) with possible contribution
to CYP3A4 variable expression.
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CYP3A4 DRUG SUBSTRATES AND PHENOTYPING
CYP3A4 is in the majority of individuals abundantly expressed
in liver but population variability is extremely high (>100-
fold). Average microsomal content has been estimated between
∼60 pmol/mg of microsomal protein (Ohtsuki et al., 2012),
110 pmol/mg (Klein et al., 2012), and ∼150 pmol/mg (Westlind-
Johnsson et al., 2003). Hepatic expression of the other CYP3A
enzymes CYP3A5, CYP3A7, and CYP3A43 is much lower in adult
Caucasians, although CYP3A5 may contribute up to about 50%
of the CYP3A pool in individuals with at least one CYP3A5∗1
allele and with low CYP3A4 expression (Hustert et al., 2001a;
Kuehl et al., 2001; Koch et al., 2002; King et al., 2003; Klees et al.,
2005; McCune et al., 2005). The role of the minor CYP3A forms
has been reviewed by others (Burk and Wojnowski, 2004; Daly,
2006). CYP3A4 is thus one of the most abundantly expressed
cytochromes in human liver contributing on average about 15–
30% to the microsomal P450 pool. Therefore and owing to their
extraordinarily broad substrate selectivity CYP3A enzymes play a
major role in the metabolism of ∼30–40% of all clinically used
drugs (Evans and Relling, 1999; Zanger et al., 2008). These include
preferentially lipophilic and bulky compounds from almost all
therapeutic categories, including tacrolimus, cyclosporin A, ery-
thromycin, ifosfamide, tamoxifen,benzodiazepines, several statins,
antidepressants,opioids, and many more,as summarized in several
previous reviews (Bu, 2006; Liu et al., 2007; Zanger et al., 2008). As
CYP3A4 is also an efficient steroid hydroxylase, it has in addition
an important role in the catabolism of several endogenous steroids
like testosterone, progesterone, cortisol, and bile acids (Patki et al.,
2003; Bodin et al., 2005).
The high sequence similarity of >85% between the CYP3A
isozymes CYP3A4 and CYP3A5 leads to highly similar substrate
selectivity between these isoforms (Williams et al., 2002). CYP3A4
and CYP3A5 activities are therefore not specifically discrim-
inable although some probe drugs showed higher selectivity for
CYP3A4-including, for example, erythromycin N -demethylation
(Wrighton et al., 1990) and atorvastatin ortho-hydroxylation
(Feidt et al., 2010). Several in vivo test substrates are available
and have been compared to each other, e.g., midazolam, ery-
thromycin, quinine, and nifedipine (Liu et al., 2007). Endoge-
nous marker activities have also been proposed as functional
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CYP3A-markers, including the 6β-hydroxylation of cortisol and
the 4β-hydroxylation of cholesterol, but some limitations due to
considerable intraindividual variability exist (Chen et al., 2006;
Fuhr et al., 2007). Remarkably, however, data obtained with dif-
ferent CYP3A substrates or endogenous markers are not generally
well correlated to each other and have therefore to be selected care-
fully with respect to the expected change in activity and design of
the study (Galteau and Shamsa, 2003; Chen et al., 2006; Fuhr et al.,
2007). Functional CYP3A phenotyping therefore continues to be
a non-trivial problem.
DEGREE OF HERITABILITY
CYP3A4 drug oxidation phenotypes are highly variable but uni-
modally distributed. Nevertheless there is indication of substantial
heritability. For example, antipyrine 4-hydroxylation rate, which is
mainly catalyzed by CYP3A4 (Engel et al., 1996), was reported to be
largely inherited (85%) as shown in early twin studies (Penno et al.,
1981). Moreover, a high degree of heritability for CYP3A4 drug
oxidation capacity toward several of its substrates (erythromycin:
89% and midazolam: 96%) was estimated by a repeated drug
administration approach (Ozdemir et al., 2000). A recent study
used a classical twin model approach in combination with a St.
John’s Wort induction regimen and quinine sulfate metabolism as
CYP3A4 activity measure to elucidate genetic versus non-genetic
contribution to variable CYP3A4 induction. Although the unin-
duced levels were not recorded, the induced CYP3A4 activity heri-
tability was estimated to be at least 66% and environmental factors
like BMI, alcohol use, and smoking habit/quantity contributed at
least 20% to the variability (Rahmioglu et al., 2011).
In contrast to the genetically polymorphic CYP2D6, which is
mostly determined genetically with only minor contribution by
environmental factors, most of the previously studied CYP3A4
polymorphisms are either rare or lack phenotypic effect and are
thus unable to explain a sizeable fraction of heritable variation. The
first documented CYP3A4 polymorphism is the frequently studied
proximal promoter variant CYP3A4∗1B (−392A>G, rs2740574)
which occurs in white populations at ∼2–9% but at higher fre-
quencies in Africans. This single nucleotide polymorphism (SNP)
was initially found to be associated with higher tumor grade
and stage in prostate cancer and showed higher nifedipine oxi-
dase activity in human livers (Rebbeck et al., 1998). Association
of CYP3A4∗1B with markers of advanced disease was confirmed
by some but not all further studies (Keshava et al., 2004; Per-
era et al., 2009). Although one in vitro study on the promoter
variant found higher transcriptional activity in cell culture exper-
iments using luciferase constructs, as well as changed protein
binding by electrophoretic mobility shift assay (Amirimani et al.,
2003), the functional effect of this variant remains questionable
given the controversial data reported in several other in vitro and
human liver studies (Wandel et al., 2000; Spurdle et al., 2002;
Rodríguez-Antona et al., 2005; Klein et al., 2012). Also, a study
with healthy volunteers phenotyped using the dextromethor-
phan/methoxymorphinan ratio failed to find an association of
CYP3A4∗1B or ∗2 with CYP3A4 activity (García-Martín et al.,
2002). Recently, resequencing and haplotype tagging studies have
been carried out at the CYP3A locus in ethnically diverse pop-
ulations (Thompson et al., 2006; Schirmer et al., 2007; Perera
et al., 2009; Perera, 2010). These studies addressed the prob-
lem of “missing heritability” of CYP3A4 phenotype variability by
considering haplotype structure at the CYP3A locus, which was
found to be of some relevance. A markedly increased occurrence
of rare variants and the presence of a homogeneous group of
long-range haplotypes at high frequency were observed in non-
African populations (Thompson et al., 2004). Because of their
involvement in the metabolism not only of naturally occurring
foreign compounds, such as flavonoids, diterpenoids, and other
herbal constituents (Zhou et al., 2007) but also of endogenous
chemicals such as uroporphyrin (Franklin et al., 2000) it has been
suggested that molecular adaptation to the changing environment
may have occurred for genes at the CYP3A locus. Thus, it has
been postulated that a region from about 40 kb upstream of the
CYP3A4 gene promoter to intron 6 was under positive selection
in humans (Thompson et al., 2004; Chen et al., 2009). In addi-
tion, despite the controversy about the CYP3A4∗1B allele, a “high
haplotype homozygosity” in European Caucasians in contrast to
African Americans was observed, which may indicate a negative
selection pressure that eliminated the ∗1B allele in non-African
populations (Schirmer et al., 2006). It should also be mentioned
that interaction between SNP/haplotype and gender have been
reported to impact on gene expression, further complicating the
situation (Schirmer et al., 2007).
An intronic variant rs4646450, located in the CYP3A5 gene,
has recently been associated with reduced tacrolimus dosage
requirement in Japanese patients (Onizuka et al., 2011), with
reduced endogenous serum dehydroepiandrosterone sulfate con-
centrations in over 14,000 individuals (Zhai et al., 2011) and was
also associated with decreased protein expression and activity of
CYP3A4 in human liver, explaining about 3–5% of hepatic vari-
ability (Klein et al., 2012). These data underline the importance of
haplotype structure throughout the CYP3A locus, and they raise
questions about causality of the various intronic and regulatory
variants. It has been suggested generally that the most penetrant
risk alleles may be of negative selective pressure and therefore be
rare (Sadee, 2012). This may have led to their oversight in small
sized screening studies or due to gene-environment interactions
which can substantially mask genetic effects (Rahmioglu et al.,
2011; Klein et al., 2012; Sadee, 2012).
Recently, however, an intron 6 variant rs35599367C>T
(CYP3A4∗22) was identified by a systematic screen for SNPs show-
ing allelic mRNA expression imbalance in human liver (Wang et al.,
2011). The effect of the variant was not confounded by sex or other
variables and it accounted for 7% of the mRNA expression vari-
ability in a cohort of 93 liver samples. Expression in cultured cells
transfected with minigenes containing exon 6, intron 6, and exon 7
reproduced the functional effect of the T-allele to decrease mRNA
in vitro, suggesting that it could be the causal variant. As no asso-
ciated splice variants or other hints to the exact mechanism were
found, the variant was supposed to affect nascent RNA elonga-
tion rate (Wang et al., 2011; Sadee, 2012). In another recent study
using 150 liver samples this variant was associated with decreased
protein levels, but not when corrections were made for multiple
testing (Klein et al., 2012).
Furthermore, the potential impact of CYP3A4 protein variants
on drug–drug interaction was emphasized in a recent in vitro study
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using recombinantly expressed variant CYP3A4 proteins 3A4.2,
3A4.7, 3A4.16, and 3A4.18, where inhibitory profile differences
of itraconazole and cimetidine were described in relation to the
CYP3A4 variants (Akiyoshi et al., 2011). Thus, although most of
the protein variants are too rare to make an impact on a population
scale, individual carriers of such variants may have risk not only
for impaired drug metabolism but also for a different drug–drug
interaction profile.
CYP3A4 POLYMORPHISMS – CLINICAL IMPACT
Most previous clinical studies that implemented CYP3A geno-
typing are not considered here because they used mainly the
CYP3A5∗3 polymorphism as marker. The reader is referred to
other reviews on this topic (Burk and Wojnowski, 2004; Daly,
2006). Table 1 shows a selection of CYP3A4-including pharmaco-
genetic in vivo studies. Although the effects of the novel intron 6
variant were not very pronounced in vitro, its impact became more
apparent by in vivo pharmacokinetic and pharmacodynamic stud-
ies. Significant association of CYP3A4∗22 with decreased AUC0−∞
ratio in atorvastatin-treated volunteers or 1.7- to 5-fold reduced
statin dose of T-allele carriers compared to non-T carriers to
achieve optimal lipid control was shown in volunteer and clinical
studies (Wang et al., 2011; Klein et al., 2012). The association of
CYP3A4∗22 with simvastatin lipid-lowering response was shown
in another clinical study (Elens et al., 2011a). Furthermore, renal
transplant recipients who were carriers of the low-expressor T-
allele had a 33% reduced mean daily-dose requirement to reach
the same tacrolimus blood concentration compared to homozy-
gotes for the wild type allele (Elens et al., 2011b) and 1.6- to
2.0-fold higher dose-adjusted trough blood levels of tacrolimus
and cyclosporine A in stable renal transplant patients (Elens et al.,
2012), both indicating lower CYP3A4 activity. Despite these con-
sistent reports, the rather low frequency of the intron 6 SNP
[global minor allele frequency (MAF) 2.1%, Caucasians 3–8%]
limits broader contribution to overall CYP3A4 variability.
CYP3A4 POLYMORPHISMS – END OF THE ROPE?
Databases are very helpful tools to get an overview on genetic
variability. However, there are major collections which serve as
basis for other online browsers (Table 2). The most important
collection of data concerning cytochrome P450 gene haplotypes
and in vitro as well as in vivo functional impact are summa-
rized in the CYPallele homepage (updated last August 31, 2011)1.
To date besides the reference CYP3A4∗1 another 21 alleles are
included, comprising at least 21 amino acid changes and 2 frame
shift variants. Although this collection is a useful resource for
functional data related to the alleles, it only provides limited infor-
mation on genetic variability. Further valuable information on
CYP3A4 SNPs and clinical pharmacogenetics is available on the
homepage of The Pharmacogenomics Knowledgebase PharmGKB2.
More comprehensive genetic information can be obtained from
other databases, which collect SNP data of diverse projects, but in
contrast to the CYPallele database or PharmGKB they lack cross
reference to documented functional impact (Table 2). The dbSNP
1http://www.cypalleles.ki.se/
2http://www.pharmgkb.org/
database3 (build 137) currently provides information on 550 SNPs
for the human CYP3A4 gene of which 21% are located within
the coding region, including 61 non-synonymous amino acid
changes, 18 synonymous, and 4 frameshift mutations. Remark-
ably, for most of the coding SNPs no MAF or reliable population
related distribution data is yet available. This may soon be over-
come by new data releases of the international “1000 Genomes
Project.” This large international collaborative project aims to gen-
erate a “Deep Catalog of Human Genetic Variation” including the
entire spectrum of all types of DNA changes from SNPs and small
indels (insertions/deletions) to large structural variations like copy
number variants and large deletions and insertions, as well as fre-
quency information and haplotype context (The 1000 Genomes
Project Consortium, 2010)4. Next generation sequencing tech-
nologies are used to sequence the complete diploid genomes of
2500 unidentified individuals from about 25 different popula-
tions. With the release of the Integrated Phase 1 Variant set in
May 2012 phased genotype calls on 1092 samples for SNPs, short
indels, and large deletions from low-coverage sequencing became
available. However, no functional or medical information is being
collected. The potential of the 1000 Genomes Project for pharma-
cogenomics has been emphasized before (Gamazon et al., 2009).
To illustrate how 1000 Genomes data may be used in pharmacoge-
netics for fine analysis, e.g., in search for causal variants, Figure 1
shows exemplarily the contribution of new SNP information to the
genomic region of CYP3A flanking the CYP3A5∗3 SNP rs776746
(±250 kb). While in the HapMap data (Figure 1A) only eight
SNPs were in strong linkage to rs776746, 49 SNPs from current
1000 Genomes dataset were identified to be in strong LD, and
interestingly also some moderately linked SNPs are located within
CYP3A4 (Figure 1B). Unfortunately, linkage information of SNPs
with potential functional impact within the CYP3A4 gene, like ∗1B
or ∗22, is not available from both datasets, probably due to missing
frequency data.
For the CYP3A4 gene the current 1000 Genomes database
release (Integrated Phase 1 Variant Set; May 2012) contains in total
471 SNPs assigned to the major transcript (ENST00000336411),
including NCBI dbSNP database content (build 134). The 1000
Genomes Project to date (accessed September 2012) contributed
129 new SNPs to this collection. Besides 115 intronic variant
positions 7 non-synonymous amino acid changes were previ-
ously unknown, of which four variants were reported on the
CYPallele homepage (∗4, ∗8, ∗11, ∗21) and only one was pre-
dicted to be deleterious by phenotype prediction tools SIFT and
PolyPhen (Table 3). However, for most of the SNPs, availabil-
ity of global MAF and population frequency data is still limited.
Although most of the novel variants are rare, it should be noted
that these can collectively make a marked contribution to the
functional population variability. For individual patients, the com-
bination of a rare deleterious variant with more frequent alleles
of low function (compound heterozygosity) can be of predictive
value. This was for example demonstrated for the polymorphic
CYP2B6 in a large clinical study with HIV patients under efavirenz
3http://www.ncbi.nlm.nih.gov/projects/SNP
4http://www.1000genomes.org
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treatment. It was shown that several individuals with elevated
efavirenz plasma concentrations could be predicted when rare
variants were considered together with the common low-expressor
∗6-allele (Rotger et al., 2007). Taking this into account, the knowl-
edge on genetic variability of ADME (Absorption Distribution
Metabolism Excretion) genes including CYP3A4 in diverse pop-
ulations will profit enormously from 1000 Genomes and new can-
didate SNPs influencing CYP3A4 expression and activity will cer-
tainly be discovered, although prediction or experimental testing
of functional impact of the many novel variants pose a challenging
task.
GENES INFLUENCING CYP3A4 PHENOTYPE OUTSIDE THE
CYP3A LOCUS
Regulation of CYP3A4 phenotype expression is enormously com-
plex including influences from networks of nuclear receptors and
other transcription factors (Pascussi et al., 2008), hormonal and
inflammatory pathways (Aitken et al., 2006), heme and protein
synthesis, and degradation pathways, as well as components of
monooxygenase complexes and their interaction partners (see in
Figure 2). Potentially influential polymorphisms in these genes
on CYP3A4 expression have been studied only in recent years by
single gene or pathway-directed approaches.
NADPH:cytochrome P450 oxidoreductase (POR) is a micro-
somal flavoprotein and an obligatory electron donator in the
microsomal P450 monooxygenase reaction. In contrast to the
multiplicity of CYPs, mammals have only a single POR gene. In
humans the gene is located on chromosome 7q11.2 and spans
about 72 kb, coding for a 680 amino acid protein. Complete dele-
tion of the por gene in mouse is embryonically lethal most likely
due to deficient adrenocortical steroidogenesis (Shen et al., 2002;
Otto et al., 2003). In contrast, liver-specific por knockout leads
to phenotypically and reproductively normal mice that accumu-
late hepatic lipids and have a drastically diminished capacity for
hepatic drug metabolism (Gu et al., 2003; Finn et al., 2007).
The amount of POR in human liver is stoichiometrically∼5- to
10-fold lower compared to the microsomal CYP pool, and hepatic
POR levels are correlated to several P450 monooxygenase activi-
ties, suggesting that it represents a limiting factor (Huang et al.,
2008a; Gomes et al., 2009). Functional polymorphisms in POR
should thus be expected to influence CYP activity. In recent
years rare POR missense mutations in humans were discovered
that impair POR function and cause disordered steroidogenesis,
ambiguous genitalia, and Antley–Bixler syndrome (Flück et al.,
2004; Flück and Pandey, 2011). The CYPalleles website currently
lists 41 distinct star-alleles,most of which represent very rare muta-
tions, but common polymorphisms also exist (Huang et al., 2005,
2008a).
In particular the A503V variation (POR∗28) is common with
frequencies ranging from 19 to 37% in all major ethnicities.
In recombinant systems the variant retained >50% of the wild
type activity toward several CYPs (Huang et al., 2008b; Sandee
et al., 2010) and CYP3A4 activity was influenced in a substrate-
dependent way (Agrawal et al., 2010). In an in vivo study it was
found that POR∗28 TT genotype was associated with a 1.6-fold
increase in CYP3A midazolam 1′-hydroxylase activity compared
with POR∗28 C carriers, a finding that could be replicated in an
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Table 2 | Overview of databases providing valuable SNP/mutation data.
Name link Infoa
Human CYPallele http://www.cypalleles.ki.se/ Overview on functional SNPs in CYP
PharmGKB http://www.pharmgkb.org/ Summarizing gene-drug-disease relationship, clinical PGx,
PGx research, and many more; referring to dbSNP_build137
dbSNP http://www.ncbi.nlm.nih.gov/projects/SNP/ NCBI database
1000 Genomes Project http://browser.1000genomes.org/index.html NGS project
SNPedia http://www.snpedia.com/index.php/SNPedia Provides information on the platforms including specific
polymorphisms
MutDB (Mooney Lab) http://www.mutdb.org/cgi-bin/mutdb.pl Data from dbSNP (NCBI) and Swiss-Prot, includes SIFT
prediction for amino acid variants
Database of genomic
variation (DGV)
http://projects.tcag.ca/variation/ All SNPs from dbSNP, overview on structural genomic
variations (CNV, segmental duplications/deletions, InDels)
GeneCards http://www.genecards.org/index.shtml dbSNP information in a compact overview with graphically
illustrated frequencies
SNAP http://www.broadinstitute.org/mpg/snap/ Displaying linkage graphically (R2 measure)
aPGx, pharmacogenomics; Swiss-Prot, manually annotated and reviewed protein knowledge base at the Swiss Institute of Bioinformatics Resource portal ExPASY;
NGS, next generation sequencing; SIFT, “sorting intolerant from tolerant” protein variant prediction tool.
independent cohort (Oneda et al., 2009). Similarly, in a cohort
of allograft recipients under tacrolimus therapy, POR∗28 T-allele
carriers had significantly higher tacrolimus dose requirements
compared to non-carriers but only if they were genotypic CYP3A5
expressors (i.e., presence of at least one CYP3A5∗1 allele; De Jonge
et al., 2011). Thus, the effect of this common POR variant appears
to depend on the CYP isozyme as well as the substrate.
Numerous additional genetic POR variants have been identified
(Hart et al., 2008; Huang et al., 2008a). With regard to CYP3A4,
several variants were described to affect its function in liver, in vitro
or in vivo. A multivariate analysis in human liver microsomes iden-
tified three intronic POR variants that affected several CYP activ-
ities and that accounted for 60% of the microsomal atorvastatin
hydroxylase variability, in concert with the donor’s sex (Gomes
et al., 2009). Chen et al. analyzed six full length protein variants for
their impact on CYP3A4-mediated testosterone hydroxylation and
on CYP2B6-mediated bupropion hydroxylation in a recombinant
system. Several POR variants showed markedly differential effects
on both activities (Chen et al., 2012). In vivo, reduction in hepatic
drug metabolizing CYP3A4 activities caused by POR mutations
was also described in patients with disordered steroid metabolism
(Flück et al., 2010). Taken together these recent advances indicate
that POR variants are a complex but potentially relevant source
of genetic variation for CYP3A-related drug oxidation phenotypes
(Miller et al., 2011).
The xenosensors pregnane X-receptor (PXR, NR1I2) and con-
stitutive androstane receptor (CAR, NR1I3) are important tran-
scription factors in the regulatory network of CYP3A4 constitu-
tive and inducible expression. Both genes are polymorphic and
genetic variants have been studied for impact on CYP3A4 tran-
scription (Lamba et al., 2005). Despite existence of numerous
alternative transcripts, naturally occurring functional polymor-
phisms of CAR that contribute to CYP3A4 phenotypic expression
are not well documented. In contrast, the functional impact of
genetic PXR variants has been studied more thoroughly. For
example, the protein variants V140M, D163G, and A370T, dis-
covered in an exon sequence screening of PXR gene in DNA
samples of several ethnicities, were shown to exhibit altered basal
or induced transactivation activity of CYP3A4 promoter using
recombinant variant expression and promoter-reporter constructs
(Hustert et al., 2001b). Resequencing analysis of 46 liver tissue
samples of Caucasian origin and hepatocytes identified SNPs in
the PXR promoter and intron 1 associated with CYP3A4 mRNA
expression, mainly due to destruction of putative transcription
factor binding sites within the regulatory region of PXR by poly-
morphisms in strong linkage (Lamba et al., 2008). Moreover, the
PXR∗1B haplotype, which is tagged by the SNPs 2654T>C and
IVS6-17C>T, was related to doxorubicin clearance in Asian breast
cancer patients (Sandanaraj et al., 2008). Further studies analyz-
ing patient cohorts under fosamprenavir/lopinavir or artemisinin
treatment gave additional hints to some PXR variants that may
affect inducibility of CYP3A4 phenotype expression (Svärd et al.,
2010; Piedade et al., 2012). The occurrence of two SNPs in the
3′UTR region of PXR, rs3732359 and rs3732360, has been shown
to be associated with altered midazolam 1′-hydroxylation in a liver
bank and with more pronounced effect in midazolam clearance of
healthy volunteers of African American descent (Oleson et al.,
2010). Two recent studies included PXR polymorphisms in their
pathway targeted pharmacogenetic approach on variable CYP3A4
expression in liver samples (Lamba et al., 2010; Klein et al., 2012).
Although in the former study PXR rs1523130 was significantly
associated with CYP3A4 mRNA expression by univariate analysis
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FIGURE 1 | Increase of SNP data information by the 1000 Genomes
Project within the CYP3A locus. LD-plots are generated for rs776746
using SNAP (http://www.broadinstitute.org/mpg/snap/ldplot.php);
250 kb region up- and downstream of the target SNP; genes are
marked by green arrows, SNPs are shown with their R2-square values
calculated versus the target SNP rs776746 (red squares) and
recombination rates are given in cM/Mb (blue line); dashed lines mark
the threshold for strong linkage R2 =0.8 (horizontal) and the
corresponding region of linked SNPs (vertical); (A) HapMap3 Release 2,
CEU (B) 1000 Genomes Pilot 1, CEU.
and in the multivariate model, the latter study did not document
a significant contribution of PXR SNPs in univariate as well as
in multivariate statistical models on mRNA, protein or activity.
In summary, contribution of PXR variants to CYP3A4 expression
remains controversial and may be limited and dependent on the
population studied.
Based on the observation that CYP3A4 and the multi-drug
resistance protein P-glycoprotein [P-gp, product of the MDR1
(ABCB1) gene] display largely overlapping substrate selectiv-
ity (Wacher et al., 1995; Patel and Mitra, 2001; Pal and Mitra,
2006), it has been hypothesized that changes in P-gp expression
may influence the intracellular concentration of endogenous or
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Table 3 | CYP3A4 coding SNPs provided by the 1000 Genomes Project (selected are the SNPs for the major transcript ENST00000336411 from
http://browser.1000genomes.org/Homo_sapiens/Search/Results?site=ensembl&q=cyp3a4) accessedSeptember 2012.
ID Chr7: bp Alleles Class Source CYPallele
(activity)a
Type Amino
acid
AA
co-ordinateb
SIFT PolyPhen
rs12721634 99381661 A/G SNP dbSNP *14 nsc L/P 15 (2) Deleterious Probably D
rs146568511 99377652 G/A SNP dbSNP nsc P/L 43 (2) Deleterious Probably D
rs56324128 99375702 C/T SNP dbSNP *7 nsc, ss G/D 56 (2) Deleterious Probably D
rs59418896 99375666 T/C SNP dbSNP nsc Y/C 68 (2) Deleterious Probably D
rs3091339 99370245 T/C SNP dbSNP nsc K/E 96 (1) Deleterious Probably D
rs142296281 99370218 G/A SNP dbSNP nsc R/W 105 (1) Deleterious Probably D
rs72552799 99367788 C/T SNP dbSNP, 1000G *8 (decr) nsc R/Q 130 (2) Deleterious Probably D
rs4987161 99366081 A/G SNP dbSNP *17 (decr) nsc F/S 189 (2) Deleterious Probably D
rs139541290 99366075 A/G SNP dbSNP nsc V/A 191 (2) Deleterious Probably D
rs55901263 99365994 G/C SNP dbSNP *5 nsc P/R 218 (2) Deleterious Probably D
rs75726589 99364854 A/G SNP dbSNP nsc L/P 233 (2) Deleterious Probably D
rs190354371 99361563 A/G SNP 1000G nsc L/P 314 (2) Deleterious Probably D
1000GENOMES_
7_99361548
99361548 T/C SNP 1000G *21 nsc Y/C 319 (2) Deleterious Probably D
rs71581998 99359841 A/T SNP dbSNP nsc V/E 359 (2) Deleterious Probably D
rs67784355 99359829 G/A SNP dbSNP, 1000G *11 (decr) nsc T/M 363 (2) Deleterious Probably D
rs113716682 99359715 A/G SNP dbSNP nsc L/P 401 (2) Deleterious Probably D
rs143966082 99359710 G/A SNP dbSNP nsc R/C 403 (1) Deleterious Probably D
rs72552797 99359685 G/A SNP dbSNP nsc P/L 411 (2) Deleterious Probably D
rs4986909 99359670 G/A SNP dbSNP *13 (decr) nsc P/L 416 (2) Deleterious Probably D
rs4986910 99358524 A/G SNP dbSNP *3 nsc M/T 445 (2) Deleterious Probably D
rs72552796 99358521 C/T SNP dbSNP nsc R/K 446 (2) Deleterious Probably D
rs71583803 99358470 A/C SNP dbSNP nsc F/C 463 (2) Deleterious Probably D
rs78764657 99377692 G/C SNP dbSNP nsc H/D 30 (1) Deleterious Possibly D
rs140422742 99375669 T/C SNP dbSNP nsc K/R 67 (2) Deleterious Possibly D
rs57409622 99367428 G/A SNP dbSNP nsc R/W 162 (1) Deleterious Possibly D
rs71581996 99361591 C/A SNP dbSNP nsc A/S 305 (1) Deleterious Possibly D
rs188389063 99381698 G/C SNP 1000G nsc L/V 3 (1) Deleterious Benign
1000GENOMES_
7_99381694
99381694 A/G SNP 1000G nsc I/T 4 (2) Deleterious Benign
COSM42988 99381647 C/T Somatic_SNV COSMIC nsc V/M 20 (1) Deleterious Benign
rs145582851 99364062 C/T SNP dbSNP nsc R/Q 268 (2) Deleterious Benign
rs148633152 99359730 A/G SNP dbSNP nsc I/T 396 (2) Deleterious Benign
rs149870259 99358596 T/C SNP dbSNP nsc K/R 421 (2) Deleterious Benign
rs28371760 99358498 A/- del dbSNP nsc, fs L/I 454 (1) Deleterious Benign
rs150559030 99358488 A/T SNP dbSNP nsc I/N 457 (2) Deleterious Benign
rs12721627 99366093 G/C SNP dbSNP *16 (decr) nsc T/S 185 (2) Tolerated Possibly D
rs55785340 99365983 A/G SNP dbSNP *2 nsc S/P 222 (1) Tolerated Possibly D
COSM35658 99381689 C/T Somatic_SNV COSMIC nsc D/N 6 (1) Tolerated Benign
rs140355261 99381687 G/C SNP dbSNP nsc D/E 6 (3) Tolerated Benign
COSM42989 99381680 T/C Somatic_SNV COSMIC nsc M/V 9 (1) Tolerated Benign
rs55951658 99367825 T/C SNP dbSNP, 1000G *4 nsc I/V 118 (1) Tolerated Benign
rs147752776 99367818 A/G SNP dbSNP nsc I/T 120 (2) Tolerated Benign
rs4986907 99367427 C/T SNP dbSNP *15 nsc R/Q 162 (2) Tolerated Benign
rs72552798 99367404 C/T SNP dbSNP *9 nsc V/I 170 (1) Tolerated Benign
rs3208361 99366070 T/C SNP dbSNP nsc I/V 193 (1) Tolerated Benign
rs113667357 99366047 T/A/C SNP dbSNP nsc Q/H 200 (3) Tolerated Benign
rs181612501 99365992 A/G SNP 1000G nsc F/L 219 (1) Tolerated Benign
rs3208363 99364798 A/C SNP dbSNP nsc S/A 252 (1) Tolerated Benign
(Continued)
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Table 3 | Continued
ID Chr7: bp Alleles Class Source CYPallele
(activity)a
Type Amino
acid
AA
co-ordinateb
SIFT PolyPhen
1000GENOMES_
7_99364768
99364768 C/T SNP 1000G nsc E/K 262 (1) Tolerated Benign
rs28371759 99361626 A/G SNP dbSNP *18 nsc L/P 293 (2) Tolerated Benign
rs138675831 99361618 C/T SNP dbSNP nsc V/M 296 (1) Tolerated Benign
1000GENOMES_
7_99361606
99361606 T/C SNP 1000G nsc I/V 300 (1) Tolerated Benign
rs10250778 99359871 G/T SNP dbSNP nsc T/N 349 (2) Tolerated Benign
rs145669559 99359812 T/C SNP dbSNP nsc I/V 369 (1) Tolerated Benign
rs12721629 99359800 G/A SNP dbSNP *12 (decr?) nsc L/F 373 (1) Tolerated Benign
rs142425279 99359734 T/C SNP dbSNP nsc M/V 395 (1) Tolerated Benign
rs139109027 99358581 T/C SNP dbSNP nsc N/S 426 (2) Tolerated Benign
rs1041988 99358566 A/G SNP dbSNP nsc I/T 431 (2) Tolerated Benign
rs4986913 99358459 G/A SNP dbSNP *19 nsc P/S 467 (1) Tolerated Benign
rs181210913 99358450 C/T SNP 1000G nsc E/K 470 (1) Tolerated Benign
rs138105638 99364063 G/A SNP dbSNP Stop R/* 268 (1) – –
rs34784390 99364036–
99364035
−/T ins dbSNP fs 277 (2) – –
rs4646438 99364035–
99364034
−/T ins dbSNP *6 fs 277 (3) – –
rs72552795 99358466–
99358465
−/G ins dbSNP fs 465 (1) – –
rs67666821 99355807–
99355806
−/T ins dbSNP *20 (no) fs 488 (1) – –
aDerived from http:// www.cypalleles.ki.se/ ; Information not provided by 1000 Genomes.
bNumber corresponds to the codon, variant nucleotide of the triplet is given brackets; nsc, non-synonymous coding; fs, frameshift; D, damaging.
exogenous substances that potentially lead to CYP3A4 induction,
thus contributing to CYP3A4 expression differences (Lamba
et al., 2006). Although data supporting this hypothesis have been
reported in one human liver association study (Lamba et al., 2010),
they were not reproduced in another study (Klein et al., 2012).
In search for additional influential genes, Lamba et al. (2010)
phenotyped 128 livers by quantitative real-time PCR for expres-
sion of CYP3A genes and identified a functional CCT-repeat poly-
morphism in the FoxA2 (HNF3α) gene to be associated with higher
expression of FoxA2 mRNA and its target genes PXR and CYP3A4.
Polymorphisms in FoxA2, HNF4α, FoxA3 (HNF3γ), PXR, MDR1,
and the CYP3A4 promoter together with sex explained 24.6% of
the variation in hepatic CYP3A4 mRNA expression. However the
study lacked information on the relevance of these variations for
CYP3A4 protein and activity.
More recently, we carried out extensive candidate gene
approaches on 150 Caucasian liver samples phenotyped for
CYP1A2 and CYP3A4 mRNA and protein levels, as well as enzyme
activity (Klein et al., 2010, 2012). With respect to CYP3A4, we
identified SNPs in the Ah-receptor nuclear translocator (ARNT ),
glucocorticoid receptor (GR), progesterone receptor membrane
component 2 (PGRMC2), and peroxisome proliferator-activated
receptor alpha (PPARA) to be consistently associated with CYP3A4
phenotype in human liver in the multivariate analysis. Vali-
dation in an atorvastatin-treated volunteer cohort confirmed
decreased atorvastatin-2-hydroxylation in carriers of PPARA
SNP rs4253728. Moreover, homozygous carriers of the variant
had reduced PPARα protein expression in liver, and shRNA-
mediated PPARA gene knock-down in primary human hepato-
cytes decreased mRNA expression levels of CYP3A4 by more than
50%. Multivariate analysis revealed that two linked PPARA SNPs
alone explained ∼8–9% of the atorvastatin hydroxylase activity
variation, whereas all genetic and non-genetic factors together
accounted for ∼33% of atorvastatin 2-hydroxylase variation in
this liver cohort (Klein et al., 2012). This result was somewhat
unexpected, because PPARα had so far not been considered as a
major regulator of CYP3A4, although inducing effects by fibrates
had been noted before in human, but not mouse primary hepato-
cytes (Prueksaritanont et al., 2005; Rakhshandehroo et al., 2009).
The interesting question of course is, whether CYP3A4 is a direct
target of PPARα or whether indirect regulation, e.g., via nuclear
receptor crosstalk resulting in downregulation of PXR (Aouabdi
et al., 2006; Takagi et al., 2008) is the causative mechanism. Recent
data from our group suggest, however, that PPARα indeed binds to
several non-consensus PPARα-response elements (PPREs) in the
CYP3A4 promoter to activate transcription in a ligand-dependent
manner (Thomas et al., 2013). Because PPARα is a master reg-
ulator of lipid homeostasis and energy balance, these results
indicate a novel connection between endogenous and xenobiotic
metabolism.
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FIGURE 2 | Regulation network of CYP3A4 phenotype expression
adapted from Klein et al. (2012). The scheme displays the promoter region
of CYP3A4 covering constitutive liver enhancer module CLEM4, xenobiotic
responsive enhancer module XREM, and the proximal promoter prP. Genes of
the constitutive and inducible pathways (Jover et al., 2002; Burk and
Wojnowski, 2004) drug transporters, inflammatory signaling
(Martínez-Jiménez et al., 2005; Aitken et al., 2006), possible miRNA
interference (Pan et al., 2009), and of the heme biosynthesis/metabolism
pathway as well as potential electron donors are listed. Genes with
documented influential polymorphisms on CYP3A4 expression are depicted in
red. Abbreviations: ALAS1, δ-aminolevulinate-synthase; ARNT, aryl
hydrocarbon receptor nuclear translocator; CAR, constitutive androstane
receptor; c/EBP, CCAAT/enhancer binding protein-α; Coup-TFII, COUP
transcription factor II; CyB5, cytochrome B5; CYP3A4, cytochrome P450 3A4;
FXR, farnesoid X-receptor; GR, glucocorticoid receptor; HMOX,
heme-oxygenase; HNF1α, hepatocyte nuclear factor 1 homeobox A; FoxA2
(HNF3β), forkhead box A2; FoxA3 (HNF3γ), forkhead box A3; HNF4α,
hepatocyte nuclear factor 4 α; IL1β, interleukin-1 β; IL1RN, interleukin-1
receptor antagonist; IL6, interleukin-6; IL6R, interleukin-6 receptor; IL6ST,
interleukin-6 signal transducer; LRH1, liver receptor homolog 1; LXRα/β, liver
X-receptor; MDR, multi-drug resistance protein; NF-κB, nuclear factor-κB
subunits; PGRMC, progesterone receptor membrane component; POR, P450
oxidoreductase; PPARα, peroxisome proliferator-activated receptor α; RARα,
retinoic acid receptor; RXRα, retinoid X-receptor; PXR, pregnane X-receptor;
SHP, short heterodimer partner; SLCO, solute carrier organic anion
transporters; USF-1, upstream stimulatory factor 1; VDR, vitamin D receptor.
NEW ASPECTS/OUTLOOK
Several genome-wide association studies with a total number
of over 1000 human liver samples identified a large number of
novel expression quantitative trait loci (eQTL) for numerous liver-
expressed genes (Schadt et al., 2008; Yang et al., 2010; Innocenti
et al., 2011; Schröder et al., 2013). Although the advantage of this
approach is the unbiased way of investigation, results were rather
disappointing with respect to CYPs, probably due to lack of statisti-
cal power. Thus, mainly polymorphisms in CYP2D6 and CYP3A5
were reproduced in these studies (Schadt et al., 2008; Schröder
et al., 2013). Building up on one eQTL study, Yang et al. used the
genome-wide SNP data of 466 livers to search for associations with
enzyme activities determined for 9 CYPs (i.e., activity- or aQTLs).
A total of 54 SNPs influencing 8 CYP activities were identified,
of which 30 influenced CYP2D6 in cis (i.e., SNPs were located
within ±1 Mb of the CYP2D6 gene), whereas all remaining 24
SNPs were described as trans-acting elements, and only one of
these (rs12041966 located on chromosome 1) influenced testos-
terone hydroxylation (Yang et al., 2010). Unfortunately, functional
annotation of the trans-acting SNPs was not possible in this study,
and these results thus await further experimental confirmation.
A further level of potential importance, which has not yet
been explored in terms of genetic variability concerns the influ-
ence of epigenetic processes on pharmacologically relevant genes
and drug response (Gomez and Ingelman-Sundberg, 2009). SNPs
in DNA methylation regions or miRNAs and miRNA binding
sites, as well as miRNA copy number variations may influence
target gene expression (Schmeier et al., 2011). Thus, CYP3A4
expression was shown to be directly regulated by miRNAs but
can also be influenced indirectly by miRNA regulation of tran-
scriptional regulators such as PXR and VDR (Pan et al., 2009).
However, polymorphic variation within this regulatory pathway
has not yet been analyzed. Furthermore, additionally to reg-
ulatory polymorphisms (rSNPs) affecting transcription, struc-
tural RNA polymorphisms (termed srSNPs) are suggested to
influence RNA function (splicing, turnover, translation) and to
display promising biomarkers (Sadee et al., 2011; Lee et al.,
2012).
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The ENCODE project (ENCyclopedia Of DNA E lements)5
systematically analyzes functional DNA elements in the human
genome (e.g., binding data for more than 100 transcription fac-
tors, DNAse sensitive sites, methylation, chromatin interaction,
and genotyping from multiple cell types) and may provide new
hypotheses on functional consequences of SNPs located especially
in non-coding DNA-regions (Bernstein et al., 2012; Gerstein et al.,
2012; Yip et al., 2012).
In conclusion, the predictive power of currently known genetic
polymorphisms with relevance for CYP3A4 in vivo phenotype is
still far away from the expected 60–80% of genetic determination.
The use of next generation sequencing approaches for the iden-
tification of causal variants in CYP3A4 as well as the numerous
genes of its many influential pathways may lead to the identifica-
tion of many more rare and common DNA variants that together
account for a sizeable fraction of this variability. The examples of
5http://genome.ucsc.edu/ENCODE/
POR and PPARA demonstrate that CYP3A4 variability is at least in
part determined by polymorphisms in genes outside the CYP3A4
locus. However, investigating and validating trans-acting factors is
much more difficult due to the more indirect nature of interaction
which is more likely to be masked by covariates, thus necessitat-
ing larger studies, in vitro or in vivo. In addition, mathematical
algorithms are needed to combine many genetic variants, some of
which contribute only small fractions to the total variability, into
practically useful signatures for application on clinical studies and
individualized medicine.
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